This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEB6U08A_M.jpg
The European Commission had fined Lundbeck and five other generic drugmakers in 2013 a combined 146 million euros for their “pay-for-delay” deals because they breached EU rules.
Lundbeck’s fine was 93.7 million euros ($104.95 million). The company subsequently challenged the EU antitrust decision at the General Court but lost in 2016, prompting it to appeal to the EU Court of Justice, Europe’s highest.
The case is C-591/16 P Lundbeck v Commission.
($1 = 0.8928 euros)
